Arrhythmia Irregular Heart Rhythm denials in California external review

In the California DMHC record, independent physician reviewers decided 90 published external-review cases involving arrhythmia irregular heart rhythmand overturned the plan’s denial in 48.9%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
90
2019–2025
Overturned
48.9%
44 denials reversed

Most-fought treatments for arrhythmia irregular heart rhythm

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
Heart Monitor15
20%
Surgery12
75%
Wearable Cardio Defib6
50%
Pacemaker Defib6
50%
Vein Ablation5
60%
Cardiac Rx4
50%
CT Scan3
0%

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
50
46%
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
39
51.3%
Typical time to a decision
11 days
Most land between 5 and 21 days
Handled as urgent
51.1%
Expedited when a delay would cause harm
Recent direction
Falling
48.6%39.5% overturned, last three years

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for convergent ablation procedure. Convergent ablation is a hybrid method that combines minimally invasive endoscopic surgical epicardial ablation with endocardial catheter ablation, typically in two stages. It reduces the risks of esophageal and phrenic nerve injury and allows direct left atrium visualization while being less invasive than full surgical ablation. Few single-center studies and at least one randomized controlled trial suggest that this procedure provides greater and longer freedom from atrial fibrillation than traditional approaches.
Experimental/Investigational · 2024 · IMR EI24-41474
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a surgical endoscopic heart procedure (CPT 33266 - operative tissue ablation and extensive reconstruction of atria without cardiopulmonary bypass).Findings: Two of the three physician reviewers found the requested surgical endoscopic heart procedure (CPT 33266 - operative tissue ablation and extensive reconstruction of atria without cardiopulmonary bypass) is likely to be more beneficial for treatment of the patient’s medical condition than any available standard therapy. A hybrid procedure of minimally invasive surgery and combined electrophysiology (EP) mapping and ablation for atrial fibrillation may overcome the shortcomings of each technique individually.
Experimental/Investigational · 2021 · IMR EI21-35624

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a leadless pacemaker. Initial data for leadless pacemakers is promising, with low incidence of complications. However, the pooled data is from small observational studies with relatively limited follow-up periods of less than one year. To date, there have been no randomized controlled trials that have directly compared the safety and efficacy of leadless pacemakers versus transvenous pacing systems, the recommended first-line option for treatment. Furthermore, according to registry data, the life span of currently available leadless pacemakers is estimated to be approximately 10 years.
Experimental/Investigational · 2023 · IMR EI23-40230
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for computed tomography (CT) scan of the heart, without contrast, with qualitative evaluation of coronary calcium. Coronary artery calcium measured by cardiac CT can help provide an estimate of total coronary plaque burden and is an established tool for cardiovascular risk stratification and preventive therapy. Several guidelines have recommended the use of coronary artery calcium testing in shared decision making between the provider and patient. However, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines do not recommend coronary artery calcium for further evaluation of patients with ventricular tachycardia (Al-Khatib, et al.).
Experimental/Investigational · 2022 · IMR EI22-37619

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving arrhythmia irregular heart rhythm, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for arrhythmia irregular heart rhythm? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9